Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Vidal-Cortes, Pablo
  • Martin-Loeches, Ignacio
  • Rodriguez, Alejandro
  • Bou, German
  • Canton, Rafael
  • Diaz, Emili
  • De la Fuente, Carmen
  • Torre-Cisneros, Julian
  • Nuvials, Francisco Xavier
  • Aguilar, Gerardo
  • Nieto, Mercedes
  • Borges, Marcio
  • Soriano, Cruz
  • Ferrer, Ricard
  • Maseda, Emilio
  • Zaragoza, Rafael

Grupos

Abstract

Infections due to Klebsiella pneumoniae have been increasing in intensive care units (ICUs) in the last decade. Such infections pose a serious problem, especially when antimicrobial resistance is present. We created a task force of experts, including specialists in intensive care medicine, anaesthesia, microbiology and infectious diseases, selected on the basis of their varied experience in the field of nosocomial infections, who conducted a comprehensive review of the recently published literature on the management of carbapenemase-producing Enterobacterales (CPE) infections in the intensive care setting from 2012 to 2022 to summarize the best available treatment. The group established priorities regarding management, based on both the risk of developing infections caused by K. pneumoniae and the risk of poor outcome. Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.

Datos de la publicación

ISSN/ISSNe:
2079-6382, 2079-6382

Antibiotics-Basel  MDPI

Tipo:
Review
Páginas:
-
PubMed:
36139940
Factor de Impacto:
0,785 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 17

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • carbapenemase-producing Enterobacterales (CPE); Klebsiella pneumoniae; KPC; VAP; nosocomial pneumonia; ceftazidime-avibactam; imipenem-relebactam; meropenem-vaborbactam; cefiderocol; ICU

Campos de Estudio

Cita

Compartir